Inhibition of ErbB3 Signaling

Recombinant human NRG1 was purchased from Cell Signaling Technology (Danvers, MA). Pertuzumab was obtained from the Thomas Jefferson University Pharmacy. huHER3-8, an ErbB3 antagonistic humanized antibody (22 (link)), was produced and purified at ImmunoGen, Inc. The monoclonal antibody, NG33, blocks NRG1 binding to the ErbB3 (25 (link)). Trametinib/GSK’212 and PD0325901 were purchased from Selleck Chemicals LLC (Houston, TX).

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Capparelli C., Rosenbaum S., Berman-Booty L.D., Salhi A., Gaborit N., Zhan T., Chervoneva I., Roszik J., Woodman S.E., Davies M.A., Setiady Y.Y., Osman I., Yarden Y, & Aplin A.E. (2015). ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas. Cancer research, 75(17), 3554-3567.

Publication 2015

Recombinant human NRG1 Trametinib/GSK’212 PD0325901

Antagonistic Antibody Gsk 212 Human Immunogen Monoclonal antibody Nrg1 Pd0325901 Pertuzumab Trametinib

Corresponding Organization :

Other organizations : Sidney Kimmel Cancer Center, Thomas Jefferson University, New York University, Weizmann Institute of Science, The University of Texas MD Anderson Cancer Center, ImmunoGen (United States), Eastern Cooperative Oncology Group

Top 5 similar protocols

Variable analysis

independent variables

Recombinant human NRG1
Pertuzumab
HuHER3-8 (ErbB3 antagonistic humanized antibody)
NG33 (monoclonal antibody that blocks NRG1 binding to ErbB3)
Trametinib/GSK'212
PD0325901

dependent variables

Not explicitly mentioned

control variables

Not explicitly mentioned

controls

Positive control: None mentioned
Negative control: None mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!